MONOCLONAL-ANTIBODY DEFINES CA 19-9 IN PANCREATIC JUICES AND SERA
MONOCLONAL-ANTIBODY DEFINES CA 19-9 IN PANCREATIC JUICES AND SERA
复制标题
DOI：
10.1136/gut.26.5.456
复制
发表时间：
1985-01-01
期刊：
影响因子：
24.5
通讯作者：
THIELE, HG
中科院分区：
文献类型：
--
作者：
SCHMIEGEL, WH;KREIKER, C;THIELE, HG
在回顾性研究中，测定了胰液样品（n = 213）和相应血清样品（n = 110）的单克隆抗体定义的CA 19-9/GICA（胃肠癌相关抗原）浓度。发现血清CA 19-9值是胰腺疾病的良好诊断和区分标志物，并且升高（> 50 μ g/ml）。ml），而胰腺炎组为8.5%，对照组无。相反，胰液CA 19-9值显示组间有相当大的重叠。基于单克隆抗体19-9定义的抗原、单唾液酸神经节苷脂和粘蛋白的最新分子数据，提出血清和胰液结果之间的差异是由于胰腺肿瘤患者中粘蛋白向血清中的特异性非定向内分泌释放，而在所有诊断组的胰液中高CA 19- 9活性是由于糖脂和粘蛋白共存或后者是生理外分泌产物。
In a retrospective study pancreatic juice samples (n = 213) and corresponding serum samples (n = 110) were assayed for their concentration of monoclonal antibody defined CA 19-9/GICA (gastrointestinal cancer associated antigen). Serum CA 19-9 values were found to be good diagnostic and discriminating markers for pancreatic disorders and were raised (> 50 .mu./ml) in more than 80% of the pancreatic cancer patients compared to 8.5% of the pancreatitis group and none of the control group. In contrast pancreatic juice CA 19-9 values showed a considerable overlap between groups. On the basis of recent molecular data on the monoclonal antibody 19-9 defined antigen(s), monosialoganglioside and mucin, it is proposed that the discrepancies between serum and pancreatic juice findings are due to a specific undirected endocrine release of the mucin into sera in pancreatic tumor patients while in pancreatic juices of all diagnostic groups high CA 19-9 activities are either owing to coexistence of glycolipid and mucin or that the latter is a physiologically exocrine product.